Matthew O Brook
Overview
Explore the profile of Matthew O Brook including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
258
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McCallion O, Cross A, Brook M, Hennessy C, Ferreira R, Trzupek D, et al.
Med
. 2024 Dec;
:100561.
PMID: 39731908
Background: Adoptive transfer of autologous regulatory T cells (Tregs) is a promising therapeutic strategy aimed at enabling immunosuppression minimization following kidney transplantation. In our phase 1 clinical trial of Treg...
2.
Mackrill S, Schramm D, Amini A, Rautemaa-Richardson R, Jones N, Brook M, et al.
Lancet Infect Dis
. 2024 Nov;
25(2):e104-e112.
PMID: 39515363
Disease associated with Cladophialophora bantiana infection is uncommon but can be characterised by severe and life-threatening CNS involvement. Diagnosis is challenging due to both the infection's rarity and non-specific clinical...
3.
Brook M, Hennessy C, Hester J, Hammad S, Alzhrani A, Rombach I, et al.
Transplantation
. 2024 Jun;
108(11):2278-2286.
PMID: 38845088
Background: The TWO Study (Transplantation Without Overimmunosuppression) aimed to investigate a novel approach to regulatory T-cell (Treg) therapy in renal transplant patients, using a delayed infusion protocol at 6 mo...
4.
Gaied J, Skinner J, Winterbottom C, Brook M, Thornley A, Turner C, et al.
Hemodial Int
. 2021 Dec;
26(2):278-280.
PMID: 34914167
No abstract available.
5.
Bottomley M, Brook M, Shankar S, Hester J, Issa F
Trends Immunol
. 2021 Nov;
43(1):8-21.
PMID: 34844848
Organ transplantation is a modern medical success story. However, since its inception it has been limited by the need for pharmacological immunosuppression. Regulatory cellular therapies offer an attractive solution to...
6.
Harden P, Game D, Sawitzki B, van der Net J, Hester J, Bushell A, et al.
Am J Transplant
. 2020 Nov;
21(4):1603-1611.
PMID: 33171020
Short-term outcomes in kidney transplantation are marred by progressive transplant failure and mortality secondary to immunosuppression toxicity. Immune modulation with autologous polyclonal regulatory T cell (Treg) therapy may facilitate immunosuppression...
7.
Jones N, Brook M, Carvalho-Gaspar M, Luo S, Wood K
Eur J Immunol
. 2010 Sep;
40(11):3107-16.
PMID: 20865790
Accumulating evidence suggests that alloreactive memory T cells (Tm) may form a barrier to tolerance induction in large animals and humans due in part to a resistance to suppression by...
8.
Carvalho-Gaspar M, Jones N, Luo S, Martin L, Brook M, Wood K
J Immunol
. 2008 May;
180(10):6640-8.
PMID: 18453583
Adaptive CD25(+)CD4(+) regulatory T cells (Treg) can be induced following exposure to alloantigen and may function alongside naturally occurring Treg to suppress allograft rejection when present in sufficient numbers. However,...
9.
Yang J, Brook M, Carvalho-Gaspar M, Zhang J, Ramon H, Sayegh M, et al.
Proc Natl Acad Sci U S A
. 2007 Nov;
104(50):19954-9.
PMID: 18042727
Alloreactive memory T cells may be refractory to many of the tolerance-inducing strategies that are effective against naive T cells and thus present a significant barrier to long-term allograft survival....
10.
Brook M, Wood K, Jones N
Transplantation
. 2006 Jul;
82(1):1-9.
PMID: 16861933
Accumulating evidence suggests that alloreactive memory T cells (Tm) may be generated in transplant recipients that have not previously been exposed to alloantigen through mechanisms such as cross-reactivity and homeostatic...